The data shows the predicted overall trend for biopharma cold chain product sales from 2016 to 2022. In 2018, it is expected that 318 billion USD worth of biopharma cold-chain products will be sold globally. A general increase in cold-chain products is expected, likely due to the ongoing transition to bio-based products, rigorous preconditions of life science shipments linked with the growing globalization of the pharmaceutical trade. Cold-chain products require colder temperatures throughout the storage, handling, and transportation processes to maintain product integrity.
